subscribeSubscribe
Amylyx stock slips 6% after phase 2 rare disease data drop

Amylyx stock slips 6% after phase 2 rare disease data drop
Gabrielle Masson FIERCE BIOTECH
11 Apr 2024
Share Share
Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers

Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers
PRESS RELEASE
05 Apr 2024
Share Share
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS

Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
PRESS RELEASE
09 Mar 2024
Share Share
RELYVRIO® and AMX0114 Data to be Presented at 34th Symposium on ALS/MND

RELYVRIO® and AMX0114 Data to be Presented at 34th Symposium on ALS/MND
BUSINESSWIRE
27 Nov 2023
Share Share
Amylyx`s ALS drug Albrioza rebuffed by EU regulator—again

Amylyx`s ALS drug Albrioza rebuffed by EU regulator—again
Zoey Becker FIERCE PHARMA
14 Oct 2023
Share Share
Amylyx to appeal EMA panel recommendation against ALS drug

Amylyx to appeal EMA panel recommendation against ALS drug
Max Gelman ENDPTS
24 Jun 2023
Share Share
Amylyx`s Relyvrio pulls in $71M in revenue

Amylyx`s Relyvrio pulls in $71M in revenue
Tyler Patchen ENDPTS
12 May 2023
Share Share
Amylyx welcomes former Alnylam exec; Amarin plugs in an interim chief

Amylyx welcomes former Alnylam exec; Amarin plugs in an interim chief
Alex Hoffman ENDPTS
21 Apr 2023
Share Share
2022 drug approvals: Biopharma delivered 37 new drugs

2022 drug approvals: Biopharma delivered 37 new drugs
Kevin Dunleavy FIERCE PHARMA
03 Jan 2023
Share Share
Amylyx`s ALS drug finally approved by FDA

Amylyx`s ALS drug finally approved by FDA
Zoey Becker FIERCEPHARMA
30 Sep 2022
Share Share